As per the current market research conducted by the CMI earch Team, the global Mycoplasma Detection System Market size is expected to record a CAGR of 12% from 2023 to 2032. In 2022, the market size is projected to reach a valuation of USD 0.8 Billion. By 2032, the valuation is anticipated to reach USD 2.3 Billion.

Mycoplasma Detection System Market: Growth Factors and Dynamics

  • Rising Awareness: Increased awareness about the detrimental effects of mycoplasma contamination on cell cultures and biopharmaceutical products is driving the demand for mycoplasma detection systems. Researchers and manufacturers are increasingly recognizing the importance of routine testing.
  • Biopharmaceutical Industry Growth: The expanding biopharmaceutical industry, driven by the development of biologics and biosimilars, necessitates stringent quality control measures, including mycoplasma testing. This sector’s growth fuels the adoption of mycoplasma detection systems.
  • Technological Advancements: Ongoing advancements in mycoplasma detection technologies, such as PCR-based assays and rapid testing methods, are enhancing the accuracy, sensitivity, and speed of detection. These innovations attract users looking for efficient testing solutions.
  • Regulatory Compliance: Stringent regulatory standards and guidelines mandate mycoplasma testing in biopharmaceutical and cell culture manufacturing. Compliance with these regulations is a significant driver of market growth.
  • Increasing Research Activities: Growing research activities in biotechnology and life sciences necessitate rigorous mycoplasma testing to maintain the integrity of experiments and studies. This drives the adoption of detection systems.
  • Global Health Concerns: The ongoing emphasis on global health, especially in light of recent health crises, underscores the importance of contamination control. Mycoplasma detection contributes to maintaining the quality of biopharmaceuticals and research outcomes.
  • Market Competition: Intense competition among mycoplasma detection system providers fosters innovation and drives product development, benefiting end-users.
  • Cost-Effective Solutions: The market is witnessing a demand for cost-effective mycoplasma detection systems, particularly in academic and research settings. Suppliers offering affordable yet reliable solutions gain a competitive edge.
  • International Collaboration: Collaboration among research institutions, biopharmaceutical companies, and testing system manufacturers facilitates the development of standardized testing protocols and best practices.
  • Supply Chain Resilience: Ensuring a resilient supply chain for mycoplasma detection reagents and equipment is crucial to meeting the increasing demand, particularly during global health events.

Report Scope

Feature of the Report Details
Market Size in 2023 USD 0.9 Billion
Projected Market Size in 2032 USD 2.3 Billion
Market Size in 2022 USD 0.8 Billion
CAGR Growth Rate 12% CAGR
Base Year 2023
Forecast Period 2024-2033
Key Segment By Product, Technology, Application, End-use and Region
Report Coverage Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends
Regional Scope North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America
Buying Options Request tailored purchasing options to fulfil your requirements for research.

Mycoplasma Detection System Market: COVID-19 Analysis

  • Increased Awareness of Contamination Risks: The pandemic underscored the importance of maintaining the integrity of cell cultures and biopharmaceutical products. Researchers and manufacturers became more aware of the risks of contamination, including mycoplasma. As a result, there has been an increased focus on routine testing using mycoplasma detection systems to prevent contamination.
  • Shift in Research Priorities: During the pandemic, there was a significant shift in research priorities towards virology and vaccine development. This heightened the need for contamination control in cell cultures and research processes, leading to greater demand for mycoplasma detection systems.
  • Impact on Supply Chains: The disruption in global supply chains, particularly in the early stages of the pandemic, affected the availability of laboratory reagents and equipment, including mycoplasma detection systems. This posed challenges for laboratories and research facilities.
  • Accelerated Technological Advancements: The urgency of the pandemic accelerated research and development efforts in the life sciences and diagnostics sectors. This led to innovations in mycoplasma detection technologies, such as the development of more rapid and sensitive testing methods.
  • Regulatory Adaptations: Regulatory agencies adapted to the challenges posed by the pandemic by providing guidance on conducting research and maintaining quality control. Compliance with these adaptations, including mycoplasma testing, became a priority for biopharmaceutical companies.
  • Remote Work and Collaboration: The need for social distancing and remote work arrangements prompted greater collaboration among researchers and laboratories. Mycoplasma detection systems with remote monitoring capabilities gained importance during this period.
  • Continued Demand: Despite the disruptions caused by the pandemic, the demand for mycoplasma detection systems remained robust, driven by the critical need to ensure contamination-free research, biopharmaceutical production, and vaccine development.

Global Mycoplasma Detection System Market 2023–2032 (By Billion)

List of the prominent players in the Mycoplasma Detection System Market:

  • InvivoGen
  • Lonza
  • Thermo Fisher Scientific Inc.
  • Eurofins Scientific
  • Bionique Testing Laboratories LLC
  • ATCC
  • Norgen Biotek Corp.
  • Bio-Rad Laboratories Inc
  • Hoffmann-La Roche Ltd.
  • Charles River Laboratories
  • Others

The Mycoplasma Detection System Market is segmented as follows:

By Product

  • Instruments
  • Kits & Reagents
    • PCR Assays
    • Nucleic Acid Detection Kits
    • Stains
    • Elimination Kits
    • Standards & Controls
    • Others
  • Services

By Technology

  • PCR
  • Direct Assay
  • Indirect Assay
  • Microbial Culture Techniques
  • Enzymatic Methods

By Application

  • Cell Line Testing
  • Virus Testing
  • End of Production Cells Testing
  • Others

By End-use

  • Academic Research Institutes
  • Cell Banks
  • Contract Research Organizations
  • Pharmaceutical & Biotechnology Companies
  • Others

Regional Coverage:

North America

  • U.S.
  • Canada
  • Mexico
  • Rest of North America


  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • New Zealand
  • Australia
  • South Korea
  • Rest of Asia Pacific

The Middle East & Africa

  • Saudi Arabia
  • UAE
  • Egypt
  • Kuwait
  • South Africa
  • Rest of the Middle East & Africa

Latin America

  • Brazil
  • Argentina
  • Rest of Latin America